A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

NCT ID: NCT04433585

Last Updated: 2024-04-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

291 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-19

Study Completion Date

2023-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3471851 High Dose

LY3471851 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3471851

Intervention Type DRUG

Administered SC

LY3471851 Mid Dose

LY3471851 administered SC.

Group Type EXPERIMENTAL

LY3471851

Intervention Type DRUG

Administered SC

LY3471851 Low Dose

LY3471851 administered SC

Group Type EXPERIMENTAL

LY3471851

Intervention Type DRUG

Administered SC

Placebo

Placebo administered SC.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3471851

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rezpegaldesleukin REZPEG NKTR-358

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a clinical diagnosis of SLE at least 24 weeks prior to screening.
* Have documentation of having met at least 4 of 11 Revised Criteria for Classification of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American College of Rheumatology (ACR) criteria for classification of SLE prior to randomization.
* Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA), and/or a positive anti-Smith (anti-Sm) as assessed by a central laboratory during screening.
* Have a total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 during screening.
* Have a clinical SLEDAI-2K score ≥4 at randomization.
* Have active arthritis and/or active rash.

Exclusion Criteria

* Have severe active lupus nephritis.
* Have active central nervous system (CNS) lupus.
* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.
* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Nektar Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Nektar Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California - San Diego

La Jolla, California, United States

Site Status

Desert Medical Advances

Palm Desert, California, United States

Site Status

Stanford University Hospital

Stanford, California, United States

Site Status

Inland Rheumatology & Osteoporosis Medical Group

Upland, California, United States

Site Status

University of Colorado School of Medicine

Aurora, Colorado, United States

Site Status

Clinical Research Center of CT/NY

Danbury, Connecticut, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Site Status

University of Miami School of Medicine

Miami, Florida, United States

Site Status

New Horizon Research Center

Miami, Florida, United States

Site Status

NECCR PrimaCare Research

Fall River, Massachusetts, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Northwell Health

Great Neck, New York, United States

Site Status

NYU Langone

New York, New York, United States

Site Status

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status

Paramount Medical Research

Middleburg Heights, Ohio, United States

Site Status

Oklahoma Medical Research Foundation

Oklahoma City, Oklahoma, United States

Site Status

Accurate Clinical Management

Baytown, Texas, United States

Site Status

Metroplex Clinical Research Center

Dallas, Texas, United States

Site Status

University of Texas Southwestern Medical Center at Dallas

Dallas, Texas, United States

Site Status

Accurate Clinical Research

Houston, Texas, United States

Site Status

Fort Bend Clinical Research, LLC

Sugar Land, Texas, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

DOM- Centro de Reumatologia

CABA, Buenos Aires, Argentina

Site Status

Centro Privado de Medicina Familiar / Mindout Research

Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina

Site Status

APRILLUS Asistencia E Investigacion de Arcis Salud

CABA, Ciudad Autónoma de Buenos Aire, Argentina

Site Status

Clinica Adventista Belgrano

CABA, Ciudad Autónoma de Buenos Aire, Argentina

Site Status

Centro de Investigaciones Médicas Tucuman

SAN M. de Tucuman, Tucumán Province, Argentina

Site Status

Hospital J. M. Ramos Mejía

Ciudad Autónoma de Buenos Aire, , Argentina

Site Status

Hospital Córdoba

Córdoba, , Argentina

Site Status

Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan

San Juan, , Argentina

Site Status

Emeritus Research

Camberwell, Victoria, Australia

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

INREA s.r.o.

Ostrava, Ostrava Město, Czechia

Site Status

Revmatologicky ustav

Prague, Praha, Hlavní Mešto, Czechia

Site Status

Universitätsklinikum Tübingen

Tübingen, Baden-Wurttemberg, Germany

Site Status

Universtitätsklinikum Essen AöR

Essen, North Rhine-Westphalia, Germany

Site Status

Rheumazentrum Ruhrgebiet

Herne, North Rhine-Westphalia, Germany

Site Status

Klinikum Bad Bramstedt GmbH

Bad Bramstedt, Schleswig-Holstein, Germany

Site Status

Universitätsklinikum Köln

Cologne, , Germany

Site Status

Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, , Germany

Site Status

Békés Megyei Központi Kórház Pándy Kálmán Tagkórház

Gyula, Bekes County, Hungary

Site Status

Qualiclinic

Budapest, , Hungary

Site Status

Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum

Debrecen, , Hungary

Site Status

Krishna Institute of Medical Science

Hyderabad, Andhra Pradesh, India

Site Status

King George Hospital

Visakhapatanam, Andhra Pradesh, India

Site Status

Amber Clinic

Ahmedabad, Gujarat, India

Site Status

Swastik Rheumatology Clinic

Ahmedabad, Gujarat, India

Site Status

Sushruta Multispeciality Hospital & Research Centre

Hubli, Karnataka, India

Site Status

Government Medical College (GMC) Aurangabad

Aurangabad, Maharashtra, India

Site Status

Government Medical College

Nagpur, Maharashtra, India

Site Status

Jasleen Hospital

Nagpur, Maharashtra, India

Site Status

All India Institute of Medical Sciences - Nagpur

Nagpur, Maharashtra, India

Site Status

Sancheti Institute for Orthopaedics & Rehabilitation

Pune, Maharashtra, India

Site Status

Center for Rheumatic Diseases

Pune, Maharashtra, India

Site Status

Sancheti HealthCare Academy

Pune, Maharashtra, India

Site Status

Sir Ganga Ram Hospital

New Delhi, National Capital Territory of Delhi, India

Site Status

Sheba Medical Center

Ramat Gan, Central District, Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Kojunkai Daido Clinic

Nagoya, Aichi-ken, Japan

Site Status

University of Occupational and Enviromental Health

Kitakyushu, Fukuoka, Japan

Site Status

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

Site Status

Tohoku University Hospital

Sendai, Miyagi, Japan

Site Status

Shinshu University Hospital

Matsumoto, Nagano, Japan

Site Status

Sasebo Chuo Hospital

Sasebo, Nagasaki, Japan

Site Status

National Hospital Organization Chibahigashi National Hospital

Chiba, , Japan

Site Status

National Hospital Organization Kyushu Medical Center

Fukuoka, , Japan

Site Status

Okayama University Hospital

Okayama, , Japan

Site Status

Daini Osaka Police Hospital

Osaka, , Japan

Site Status

St. Luke's International Hospital

Tokyo, , Japan

Site Status

Keio university hospital

Tokyo, , Japan

Site Status

CIMAB SA de CV

Torreón, Coahuila, Mexico

Site Status

Centro Medico del Angel

Mexicali, Estado de Baja California, Mexico

Site Status

Centro Integral en Reumatologia

Guadalajara, Jalisco, Mexico

Site Status

Clinica de Investigacion en Reumatologia y Obesidad S. C.

Guadalajara, Jalisco, Mexico

Site Status

RM Pharma Specialists S.A. de C.V.

Mexico City, Mexico City, Mexico

Site Status

Clinica para el Diagnostico y Tratamiento de la Enfermedades

Mexico City, Mexico City, Mexico

Site Status

MICS Centrum Medyczne Warszawa

Warsaw, Masovian Voivodeship, Poland

Site Status

Nova Reuma Społka Partnerska

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Nzoz Bif-Med

Bytom, Silesian Voivodeship, Poland

Site Status

Szpital Uniwersytecki Nr 2 w Bydgoszczy

Bydgoszcz, , Poland

Site Status

Centro Reumatologico Caguas

Caguas, PR, Puerto Rico

Site Status

Latin Clinical Trial Center

San Juan, PR, Puerto Rico

Site Status

GCM Medical Group, PSC - Hato Rey Site

San Juan, PR, Puerto Rico

Site Status

Mindful Medical Research

San Juan, PR, Puerto Rico

Site Status

C.M.D.T.A. Neomed

Brasov, Brașov County, Romania

Site Status

SC Centrul Medical Sana SRL

Bucharest, , Romania

Site Status

Spitalul Clinic Sf Maria Bucuresti

Bucharest, , Romania

Site Status

Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei

Galati, , Romania

Site Status

Karelia Republican Hospital V.A. Baranova

Petrozavodsk, Kareliya, Respublika, Russia

Site Status

Moscow City Clinical Hospital Number 15

Moscow, Moscow, Russia

Site Status

V.A. Nasonova Research Institute of Rheumatology

Moscow, , Russia

Site Status

Ryazan Regional Clinical Cardiology Dispensary

Ryazan, , Russia

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Inha University Hospital

Incheon, Korea, South Korea

Site Status

Kyung Hee University Hospital

Seoul, Korea, South Korea

Site Status

Hanyang University Medical Center

Seoul, Korea, South Korea

Site Status

Seoul National University Hospital

Seoul, Seoul, Korea, South Korea

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Quiron Infanta Luisa

Seville, , Spain

Site Status

Chang Gung Memorial Hospital - Kaohsiung Branch

Kaohsiung City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Regional Clinical Hospital Center for Emergency medical care

Kharkiv, , Ukraine

Site Status

Edelweiss Medics LLC

Kyiv, , Ukraine

Site Status

Kyiv City Clinical Hospital #3

Kyiv, , Ukraine

Site Status

Multifield Medical Center of Odesa NMU (University Clinic#1)

Odesa, , Ukraine

Site Status

Vinnytsya Regional Clinical Hospital

Vinnytsia, , Ukraine

Site Status

Regional Clinical Hospital of Zaporizhzhia

Zaporizhzhia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Canada Czechia Germany Hungary India Israel Japan Mexico Poland Puerto Rico Romania Russia South Korea Spain Taiwan Ukraine

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://trials.lillytrialguide.com/en-US/trial/2NrKmN7Zwj52k3UG9QrLqS

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

J1P-MC-KFAJ

Identifier Type: OTHER

Identifier Source: secondary_id

2019-003323-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

17422

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Daratumumab to Treat Active Lupus Nephritis
NCT04868838 ACTIVE_NOT_RECRUITING PHASE2